Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
2
WOK Quote, Financials, Valuation and Earnings
Last price:
$0.05
Seasonality move
:
-88.01%
Day range:
$0.05 - $0.05
52-week range:
$0.05 - $600.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.90x
P/B ratio:
3.41x
Volume:
42.1M
Avg. volume:
36M
1-year change:
-99.99%
Market cap:
$55.1K
Revenue:
$11.5M
EPS (TTM):
-$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WOK
WORK Medical Technology Group Ltd.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$130.3M | -$0.23 | 16.92% | -46.43% | $49.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WOK
WORK Medical Technology Group Ltd.
|
$0.05 | -- | $55.1K | -- | $0.00 | 0% | 0.90x |
|
ADAG
Adagene, Inc.
|
$1.82 | $9.22 | $85.7M | -- | $0.00 | 0% | 819.10x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.81 | $4.00 | $16.6M | -- | $0.00 | 0% | 0.47x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.41 | -- | $4.6M | -- | $0.00 | 0% | 1.14x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$18.04 | $49.49 | $2B | -- | $0.00 | 0% | 4.38x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WOK
WORK Medical Technology Group Ltd.
|
58.17% | 3.819 | -- | 0.26x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WOK
WORK Medical Technology Group Ltd.
|
-- | -- | -5.23% | -9.65% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
WORK Medical Technology Group Ltd. vs. Competitors
-
Which has Higher Returns WOK or ADAG?
Adagene, Inc. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of --. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About WOK or ADAG?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 406.83%. Given that Adagene, Inc. has higher upside potential than WORK Medical Technology Group Ltd., analysts believe Adagene, Inc. is more attractive than WORK Medical Technology Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is WOK or ADAG More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WOK or ADAG?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or ADAG?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. WORK Medical Technology Group Ltd.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.90x versus 819.10x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.90x -- -- -- ADAGAdagene, Inc.819.10x -- -- --
-
Which has Higher Returns WOK or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of -353.92%. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About WOK or CASI?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 393.83%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than WORK Medical Technology Group Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than WORK Medical Technology Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is WOK or CASI More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock WOK or CASI?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or CASI?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. WORK Medical Technology Group Ltd.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.90x versus 0.47x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.90x -- -- -- CASICASI Pharmaceuticals, Inc.0.47x -- $3.1M -$10.9M
-
Which has Higher Returns WOK or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of -86.16%. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About WOK or CPHI?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that WORK Medical Technology Group Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe WORK Medical Technology Group Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is WOK or CPHI More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock WOK or CPHI?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or CPHI?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. WORK Medical Technology Group Ltd.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.90x versus 1.14x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.90x -- -- -- CPHIChina Pharma Holdings, Inc.1.14x -- $756.2K -$651.5K
-
Which has Higher Returns WOK or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of --. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About WOK or SVA?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that WORK Medical Technology Group Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe WORK Medical Technology Group Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is WOK or SVA More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock WOK or SVA?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or SVA?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. WORK Medical Technology Group Ltd.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.90x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.90x -- -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns WOK or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of -30.98%. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About WOK or ZLAB?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 174.33%. Given that Zai Lab Ltd. has higher upside potential than WORK Medical Technology Group Ltd., analysts believe Zai Lab Ltd. is more attractive than WORK Medical Technology Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is WOK or ZLAB More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock WOK or ZLAB?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or ZLAB?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. WORK Medical Technology Group Ltd.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.90x versus 4.38x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.90x -- -- -- ZLABZai Lab Ltd.4.38x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
